Ionis Pharmaceuticals (IONS) Depreciation & Amortization (CF) (2013 - 2026)

Ionis Pharmaceuticals' Depreciation & Amortization (CF) history runs 14 years deep, the most recent figure standing at $3.3 million for Q1 2026.

• On a quarterly basis, Depreciation & Amortization (CF) rose 48.16% year-over-year to $3.3 million in Q1 2026; TTM through Mar 2026 was $11.1 million, a 19.21% increase from a year earlier, with the FY2025 full-year figure at $10.0 million, up 4.1% from the prior year.
• Depreciation & Amortization (CF) climbed to $3.3 million in Q1 2026 per IONS's latest filing, from $3.3 million in the prior quarter.
• Across five years, Depreciation & Amortization (CF) topped out at $3.8 million in Q3 2022 and bottomed at $2.2 million in Q1 2025.
• The 5-year median for Depreciation & Amortization (CF) is $2.5 million (2024), against an average of $2.8 million.
• Across the five-year window, Depreciation & Amortization (CF) plunged 33.9% in 2023 and jumped 48.16% in 2026, its largest moves.
• Year by year, Depreciation & Amortization (CF) stood at $3.0 million in 2022, then declined by 15.96% to $2.5 million in 2023, then retreated by 11.95% to $2.2 million in 2024, then soared by 45.49% to $3.3 million in 2025, then gained by 1.29% to $3.3 million in 2026.
• Per Business Quant, the three latest IONS Depreciation & Amortization (CF) figures stand at $3.3 million (Q1 2026), $3.3 million (Q4 2025), and $2.3 million (Q3 2025).